Moving forward in tackling antimicrobial resistance: WHO actions

被引:13
作者
Lusti-Narasimhan, Manjula [1 ]
Pessoa-Silva, Carmem L. [2 ]
Temmerman, Marleen [1 ]
机构
[1] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland
[2] WHO, HQ HSE PED, AMR, CH-1211 Geneva 27, Switzerland
关键词
GONORRHOEA; HEALTH PROMOTION; ANTIMICROBIAL RESISTANCE; CEFTRIAXONE TREATMENT;
D O I
10.1136/sextrans-2012-050910
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although the key focus of this supplement is related to antimicrobial resistance (AMR) in a sexually transmitted infection, Neisseria gonorrhoeae, the purpose of this article is to highlight the wider public health impact of AMR and the need for different disciplines of health to coordinate and collaborate in their selection and use of antimicrobial agents. AMR is being detected in health areas ranging from simple drugs used to treat common bacterial infections to the complex formulations used to treat tuberculosis, malaria and HIV infection, and on all continents. Tackling and containing AMR present an ordeal to international and national health authorities on many fronts. In June 2012, WHO launched the WHO Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae with a vision to enhance the global response to the prevention, diagnosis and control of N gonorrhoeae infection and mitigate the health impact of AMR through enhanced, sustained, evidence-based and collaborative multisectoral action. This global action plan is positioned within a long-standing commitment of WHO to the issue of AMR with the launch of the Global Strategy on AMR in 2001 and World Health Day on AMR in 2011.
引用
收藏
页码:57 / 59
页数:3
相关论文
共 10 条
  • [1] Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
    Chisholm, Stephanie A.
    Mouton, Johan W.
    Lewis, David A.
    Nichols, Tom
    Ison, Catherine A.
    Livermore, David M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) : 2141 - 2148
  • [2] Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic
    David, Michael Z.
    Daum, Robert S.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (03) : 616 - +
  • [3] Resistance in gram-negative bacteria: Enterobacteriaceae
    Paterson, David L.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2006, 119 (06) : S20 - S28
  • [4] Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods
    Tapsall, John
    Read, Phillip
    Carmody, Christopher
    Bourne, Christopher
    Ray, Sanghamitra
    Limnios, Athena
    Sloots, Theo
    Whiley, David
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2009, 58 (05) : 683 - 687
  • [5] Unemo M, 2011, EUROSURVEILLANCE, V16, P5
  • [6] Unemo M, 2010, EUROSURVEILLANCE, V15, P9
  • [7] Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime -: Hawaii, 2001
    Wang, SA
    Lee, MVC
    O'Connor, N
    Iverson, CJ
    Ohye, RG
    Whiticar, PM
    Hale, JA
    Trees, DL
    Knapp, JS
    Effler, PV
    Weinstock, HS
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 849 - 852
  • [8] WHO, TECHN CONS STRAT GLO
  • [9] World Health Organization, 2001, WHO Global Strategy for Containment of Antimicrobial Resistance
  • [10] World Health Organization, 2012, GLOB ACT PLAN CONTR